eli lilly and tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Eli Lilly (LLY) Gets Nod

Additional Information:

GLP-1 RAs have shown consistent results in managing blood glucose levels by lowering HbA1c with minimal hypoglycemic risk and increasing insulin production and synthesis

Cardiovascular outcomes have been studied in diabetes programs, but long-term cardiovascular and renal effects need continued follow-up through registries and post-marketing safety data

Related Stories GLP-1 weight loss may reduce first-impression penalties in relationships and hiring New laser technology detects counterfeit alcohol through sealed bottles Weight loss drugs may reduce binge eating disorder symptoms Simultaneously, a growing body of evidence suggests that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) are capable of crossing the blood-brain barrier (BBB) and interacting with the brain's reward and dopamine signaling regions, leading researchers to hypothesize that these originally weight-management-centric drugs could be used to address addictive behaviors, specifically regarding the suppression of ethanol-seeking triggers

Understanding free radicals and inflammation in our bodies is critical

Double Diabetes: A Growing Problem Requiring Solutions